Calcitonin News and Research RSS Feed - Calcitonin News and Research

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.
New class of anti-arthritic drugs reduce arthritic joint inflammation and periodontitis

New class of anti-arthritic drugs reduce arthritic joint inflammation and periodontitis

Inflammatory diseases can occur simultaneously in distinct sites in the same patient, complicating treatment because a medication effective for one disorder may exacerbate the other. [More]
Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities. [More]
Pain receptors may hold key to treating obesity, diabetes and improving metabolic health

Pain receptors may hold key to treating obesity, diabetes and improving metabolic health

Blocking a pain receptor in mice not only extends their lifespan, it also gives them a more youthful metabolism, including an improved insulin response that allows them to deal better with high blood sugar. [More]
Inflammation may accentuate age-related bladder function decline

Inflammation may accentuate age-related bladder function decline

Age-associated biochemical changes in the bladder may accentuate the inflammation associated with overactive bladder, study findings indicate. [More]
New studies may offer hope for people with migraine

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. [More]
Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. [More]
Research: Neuropeptides may serve as index for evaluating early peripheral nerve injury

Research: Neuropeptides may serve as index for evaluating early peripheral nerve injury

Substance P and calcitonin gene-related peptide are the main neuropeptides in peripheral nerve ganglia, which can anterogradely transmit nociceptive information to the central nervous system. [More]
Transient receptor potential channel A1 causes calcitonin gene-related peptide release in neurons

Transient receptor potential channel A1 causes calcitonin gene-related peptide release in neurons

Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia. [More]
New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

BBI Solutions, a world leader in immunoassay development and contract manufacturing, recently launched its unique range of Recombinant Fab Monoclonal Antibodies at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas. [More]
Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

The prevalence of skin disease exceeds that of obesity, hypertension or cancer. One in three individuals in the United States suffers with a skin disease, with ~2-3% of the American population suffering from psoriasis. [More]
Neuroprotective effects of rutaecarpine on cerebral ischemia reperfusion injury

Neuroprotective effects of rutaecarpine on cerebral ischemia reperfusion injury

Rutaecarpine, an active component of the traditional Chinese medicine Tetradium ruticarpum, has been shown to improve myocardial ischemia reperfusion injury, mainly focusing on calcitonin gene-based targets. [More]
Basic fibroblast growth factor can protect endplate in motor neurons of injured spinal cord

Basic fibroblast growth factor can protect endplate in motor neurons of injured spinal cord

In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections. [More]
Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

​Dermatology researcher Nicole Ward, PhD, has earned her third National Institutes of Health grant in a year - including two that scored in the first percentile. With this most recent award, an R21, she will investigate the role the nervous system plays in psoriasis - an inflammatory autoimmune disease characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin. [More]
GSD receives FDA Clearance for 25-OH Vitamin D Total ELISA test

GSD receives FDA Clearance for 25-OH Vitamin D Total ELISA test

Gold Standard Diagnostics, Corp., a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, announced 510k FDA Clearance of its 25-OH Vitamin D, Total ELISA. [More]
Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute. [More]
Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology. [More]
AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized). [More]
Calcium-related hormone could help identify pneumonia

Calcium-related hormone could help identify pneumonia

Serum procalcitonin measurements could improve the accuracy of pneumonia diagnoses when chest radiographs give indeterminate results, indicate US study findings. [More]
Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease. [More]
Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). [More]